What is stage 2 Chronic Kidney Disease (CKD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 21, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Stage 2 kidney disease is characterized by a mild reduction in kidney function, with an estimated glomerular filtration rate (eGFR) ranging from 60 to 89 mL/min/1.73m², as defined by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative for CKD 1.

Key Characteristics of Stage 2 Kidney Disease

  • The eGFR range of 60-89 mL/min/1.73m² indicates that the kidneys are filtering blood at about 60-89% of normal capacity.
  • Most people with stage 2 kidney disease do not experience symptoms, as the body can adapt to the mild decrease in kidney function.
  • This stage is often discovered through routine blood or urine tests that show markers of kidney damage, such as protein in the urine (proteinuria) or elevated creatinine levels.

Causes and Management of Stage 2 Kidney Disease

  • Common causes of stage 2 kidney disease include diabetes, high blood pressure, inflammatory diseases, or inherited kidney disorders.
  • Management focuses on treating underlying conditions, controlling blood pressure (often with medications like ACE inhibitors or ARBs), managing blood sugar if diabetic, following a kidney-friendly diet, exercising regularly, avoiding nephrotoxic medications, and having regular check-ups to monitor kidney function, as recommended by the American Journal of Kidney Diseases 2.
  • Early intervention at this stage is crucial, as it can significantly slow progression to more advanced kidney disease, and evaluation and control of dyslipidemia and other cardiovascular disease risk factors are also important, as noted in the study published in the American Journal of Kidney Diseases 2.

Importance of Early Intervention

  • Early intervention in stage 2 kidney disease is critical to slow disease progression and reduce the risk of complications, as emphasized by the National Kidney Foundation practice guidelines for chronic kidney disease 3.
  • Treatment of comorbid conditions, interventions to slow progression of kidney disease, and measures to reduce the risk for cardiovascular disease should begin during stage 1 and stage 2, as recommended by the Annals of Internal Medicine 3.

From the Research

Definition of Stage 2 Kidney Disease

Stage 2 kidney disease is characterized by a mild loss of kidney function, with an estimated glomerular filtration rate (eGFR) of 60-89 mL/min/1.73m² 4.

Key Characteristics

  • eGFR: 60-89 mL/min/1.73m²
  • Mild loss of kidney function
  • May be associated with other health problems, such as high blood pressure or diabetes

Treatment and Management

Treatment for stage 2 kidney disease typically involves lifestyle changes and medications to manage related health conditions, such as:

  • Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) to control blood pressure and reduce proteinuria 5, 6
  • Calcium channel blockers to control blood pressure 4
  • Lifestyle changes, such as a healthy diet and regular exercise, to manage related health conditions

Important Considerations

  • ACEIs and ARBs may be beneficial in reducing proteinuria and slowing CKD progression, but may also have potential risks, such as worsening renal failure in some patients 7
  • Individualized therapy based on patient-specific factors is important to optimize renal and cardiovascular outcomes 4

Related Questions

For a patient with an estimated glomerular filtration rate of 44 mL/min/1.73 m², what is the appropriate initial dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)?
What is the best angiotensin‑II receptor blocker (ARB) to start in an adult patient with chronic kidney disease stage 3‑4, proteinuria, and an estimated glomerular filtration rate of 36 mL/min/1.73 m²?
Which angiotensin‑converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs) are most effective for reducing proteinuria?
Can a person with Chronic Kidney Disease (CKD) take an Angiotensin-Converting Enzyme (ACE) inhibitor like Lisinopril (Zestril)?
For a patient with persistent albuminuria on ACE‑inhibitor/ARB therapy, at which CKD stage and albuminuria thresholds are N‑acetylcysteine and taurine beneficial, and when are alpha‑keto analogues indicated?
What warning labels are associated with Gemtesa (vibegron)?
Can Gastroesophageal Reflux Disease (GERD) cause palpitations?
What device is used over a cervical spine fusion to promote bone growth?
Can mirtazapine (Remeron) be used in a patient with decompensated liver cirrhosis?
Can Zosyn (piperacillin/tazobactam) be used in a patient with decompensated cirrhosis?
What is the maximum duration for using Elidel (pimecrolimus) cream on a 9-month-old child with severe atopic dermatitis, and what is the recommended protocol for its use, including gradual withdrawal or cessation and potential re-initiation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.